

# (12) International Application Status Report

**Received at International Bureau:** 11 June 2017 (11.06.2017)

**Information valid as of:** 14 November 2017 (14.11.2017)

**Report generated on:** 21 March 2019 (21.03.2019)

**(10) Publication number:**

WO2017/206940

**(43) Publication date:**

07 December 2017 (07.12.2017)

**(26) Publication language:**

English (EN)

**(21) Application Number:**

PCT/CN2017/086942

**(22) Filing Date:**

02 June 2017 (02.06.2017)

**(25) Filing language:**

English (EN)

**(31) Priority number(s):**

62/344,660 (US)

**(31) Priority date(s):**

02 June 2016 (02.06.2016)

**(31) Priority status:**

Priority document received (in compliance with PCT Rule 17.1)

**(51) International Patent Classification:**

**A61K 9/107** (2006.01); **A61K 9/48** (2006.01); **A61K 31/7068** (2006.01); **A61P 35/00** (2006.01)

**(71) Applicant(s):**

INNOPHARMAX, INC. [CN/CN]; 9F., No.22, Lane 478, Rueiguang Rd. Neihu District Taipei 11492, Taiwan (CN) *(for all designated states)*

**(72) Inventor(s):**

HAO, Wei-Hua; 9F., No.22, Lane 478, Rueiguang Rd. Neihu District Taipei 11492, Taiwan (CN)  
HSUEH, Shu-Piing; 9F., No.22, Lane 478, Rueiguang Rd. Neihu District Taipei 11492, Taiwan (CN)  
HSU, Chang-Shan; 9F., No.22, Lane 478, Rueiguang Rd. Neihu District Taipei 11492, Taiwan (CN)

**(74) Agent(s):**

GE CHENG & CO., LTD.; Level 19, Tower E3, The Towers, Oriental Plaza No.1, East Chang An Avenue Dongcheng District Beijing 100738 (CN)

**(54) Title (EN):** METRONOMIC ORAL GEMCITABINE FOR CANCER THERAPY

**(54) Title (FR):** GEMCITABINE MÉTRONOMIQUE ADMINISTRÉE PAR VOIE ORALE POUR LE TRAITEMENT DU CANCER

**(57) Abstract:**

**(EN):** Use of gemcitabine, including in self-emulsifying orally administered dosage forms for treatment, such as inducing regression or inhibiting growth, of tumors in a patient such as a human. Gemcitabine is orally administered in a metronomic manner.

**(FR):** L'invention concerne l'utilisation de gemcitabine, y compris dans des formes posologiques à administration orale auto-émulsifiantes pour le traitement, par exemple l'induction de la régression ou l'inhibition de la croissance, de tumeurs chez un patient tel qu'un être humain. La gemcitabine est administrée par voie orale de manière métronomique.

**International search report:**

Received at International Bureau: 14 September 2017 (14.09.2017) [CN]

**International Report on Patentability (IPRP) Chapter II of the PCT:**

Not available

**(81) Designated States:**

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE,

PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM